

Date: 2nd September, 2020

To,
BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001.
Scrip Code: 511523

Sub.: Unaudited Financial Results for the quarter ended June 30, 2020


Dear Sir,

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

1. Statement showing the Unaudited Financial Results for the quarter ended June 30, 2020.
2. Limited Review Report on the Unaudited Financial Results for the quarter ended June 30, 2020.

Thanking You.

Yours faithfully,
For **Veerhealth Care Limited**



Yogesh M. Shah
Director
DIN: 00169189



Encl: As above

VEERHEALTH CARE LIMITED
 Regd Office: 629-A, Gazdar House, 1st Floor, J.S.S. Marg, Near Kalbadevi Post Office, Mumbai - 400002.
 Tel. No. 022-22018582 Fax. No. 022-22072644 CIN: L65910MH1992PLC067632
 Email: info@veerhealthcare.net Website: www.veerhealthcare.net

Statement of Unaudited Financial Results for the Quarter ended June 30, 2020

(Rs. in lakhs)

Sr. No.	Particulars	Standalone			
		Quarter ended 30-06-2020	Quarter ended 31-03-2020	Quarter ended 30-06-2019	Year ended 31-03-2020
		Unaudited	Audited	Unaudited	Audited
I	Revenue from operations	164.92	355.71	206.82	1172.79
II	Other Income	11.14	-15.05	22.59	48.15
III	Total Revenue (I + II)	176.06	340.66	229.41	1220.94
IV	Expenses:				
	(a) Cost of materials consumed	0.00	0.00	0.00	0.00
	(b) Purchase of stock-in-trade	155.48	228.27	188.33	827.30
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-41.55	9.19	-61.11	-38.97
	(d) Employee benefits expense	17.67	25.45	15.39	79.75
	(e) Finance Costs	0.02	6.35	0.11	19.01
	(f) Depreciation and amortisation expense	11.48	8.10	7.99	32.32
	(g) Other expenses	25.56	119.62	52.84	236.83
	Total Expenses	168.66	396.98	203.55	1156.24
V	Profit/(Loss) before exceptional items (III - IV)	7.40	-56.32	25.86	64.70
VI	Exceptional items	0.00	0.00	0.00	0.00
VII	Profit before tax (V - VI)	7.40	-56.32	25.86	64.70
VIII	Tax expense:				
	1) Current Tax	1.50	-9.30	5.00	14.70
	2) Prior Year Tax	0.00	0.91	0.00	0.91
	2) Deferred Tax	0.00	17.25	0.00	17.25
IX	Profit/(Loss) for the period (VII - VIII)	5.90	-65.18	20.86	31.84
X	Other Comprehensive Income				
	(a) Items that will not be reclassified to Profit or Loss	0.55	1.26	0.28	2.10
	(b) Income Tax effect on above	0.00	0.00	0.00	0.00
	Other Comprehensive Income	0.55	1.26	0.28	2.10
XI	Total Comprehensive Income for the period (IX + X)	6.45	-63.92	21.14	33.94
XII	Paid-up equity share capital of Rs. 10 each	693.42	693.42	693.42	693.42
XIII	Other Equity				682.21
XIV	Earnings Per Share (of Rs. 10 each):				
	(a) Basic (in Rs.)	0.09	-0.94	0.30	0.46
	(b) Diluted (in Rs.)	0.09	-0.94	0.30	0.46



[Handwritten signature]

VEERHEALTH CARE LIMITED

Regd Office: 629-A, Gazdar House, 1st Floor, J.S.S. Marg, Near Kalbadevi Post Office, Mumbai - 400002.
Tel. No. 022-22018582 Fax. No. 022-22072644 CIN: L65910MH1992PLC067632
Email: info@veerhealthcare.net Website: www.veerhealthcare.net


NOTES:

- 1 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 2nd September, 2020. The Limited Review under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been carried out by the Statutory Auditors. The limited review report does not contain any observation which would have an impact on the above results.
- 2 The standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ('IND AS') prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and guidelines issued by the Securities and Exchange Board of India ("SEBI").
The spread of COVID-19 has severely impacted business around the globe. In many countries including India, there has been severe disruption to regular business operations due to lock-down, disruptions in transportation, supply chain, travel bans, quarantines, social distancing and other emergency measures. The Company has made detailed assessment of its liquidity position for the next one year and has concluded that there is no material adjustments required in the financial results for the quarter ended June 30, 2020. Management believes that it has considered all the possible impact of known events arising from COVID-19 pandemic in the preparation of the financial results for the quarter ended June 30, 2020. However, the impact assessment of COVID-19 is a continuing process given the uncertainties associated with its nature and duration. The Company will continue to monitor any material changes to future economic conditions.
- 4 During the quarter ended June 30, 2020 the Company is operating in a single segment i.e. "Ayurved Pharma Products". Accordingly, segment wise reporting is not applicable.
- 5 The figures of the previous period/ year have been rearranged / regrouped wherever necessary.
- 6 The financial results of the Company are available at www.bseindia.com, at www.msei.in and at www.veerhealthcare.net.

Place: Mumbai
Date: 2nd September, 2020



By order of the Board
For Veerhealth Care Limited


Yogesh M. Shah
Director
DIN: 00169189



Limited Review Report

Review Report to the Board of Directors of Veerhealth Care Limited

We have reviewed the accompanying statement of unaudited financial results of M/s. Veerhealth Care Limited ("the Company") for the quarter ended June 30, 2020. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an Audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

For M. H. Dalal & Associates
Chartered Accountants
FRN: 112449W

Devang M. Dalal
Partner

M. No. 109049

UDIN:- 20109049AAAAOL8865

Place: Mumbai

Date: 2nd September, 2020

